Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.74 |
| ▸ | NPC1 | O15118 | 11/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 7/20 | 0.74 |
| ▸ | NFKB2 | Q00653 | 7/20 | 0.74 |
| ▸ | RELA | Q04206 | 7/20 | 0.74 |
| ▸ | MAPT | P10636 | 5/20 | 0.74 |
| ▸ | TP53 | P04637 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | HTT | P42858 | 3/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | PLAU | P00749 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MELK | Q14680 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28256407 | 0.84 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL29669746 | 0.84 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL8460943 | 0.83 | RAB9A (0.75) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL20078361 | 0.82 | RAB9A (0.83) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL7430798 | 0.79 | PLAU (0.76) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL28256463 | 0.79 | LY96 (1.00) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL21468516 | 0.78 | NPC1 (0.68) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL13170480 | 0.78 | NPC1 (0.86) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL28256405 | 0.78 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL29669668 | 0.78 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | claimed |
| CN-103664973-A | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2014-03-26 | — | — | CN | claimed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| US-20170114075-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-04-27 | — | — | US | disclosed |
| US-9458178-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
| EP-2942350-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2015-11-11 | — | — | EP | disclosed |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | disclosed |
| US-8916580-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2014-12-23 | — | — | US | disclosed |
| CN-103664973-A | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2014-03-26 | — | — | CN | disclosed |
| US-20130252962-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2013-09-26 | — | — | US | disclosed |
| US-8415370-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-04-09 | — | — | US | disclosed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | disclosed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114075-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | RAB9A 1615/4885NPC1 790/4885SMN1; SMN2 289/4885 |
| US-20130252962-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | RAB9A 1615/4885NPC1 790/4885SMN1; SMN2 289/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | RAB9A 1615/4885NPC1 790/4885SMN1; SMN2 289/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | RAB9A 1619/4885NPC1 804/4885SMN1; SMN2 272/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | RAB9A 1615/4885NPC1 790/4885SMN1; SMN2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.